Johnson & Johnson subsidiary Janssen Inc. believes that its oral anticoagulant Xarelto (rivaroxaban) is on its way to having the broadest label of any of the novel anticoagulant agents.
With positive findings in treatment of symptomatic pulmonary embolism and prevention of recurrent events from the EINSTEIN-PE trial, it may be the first to crack an important indication that, until now, has been under the radar. The EINSTEIN-PE trial showed non-inferior efficacy for Xarelto and a 50% reduction in major bleeding compared to the standard of care